In a filing, Madrigal Pharmaceuticals Inc revealed its Officer and Director William John Sibold acquired Company’s shares for reported $3.3 million on Sep 09 ’25. In the deal valued at $453.80 per share,7,279 shares were bought.
Then, Sibold William John sold 7,279 shares, generating $3,243,741 in total proceeds. Upon selling the shares at $445.63, the President and CEO now owns 102,474 shares.
Before that, FRED CRAVES bought 2,900 shares. Madrigal Pharmaceuticals Inc shares valued at $1,251,896 were divested by the Former Director at a price of $431.69 per share.
BofA Securities upgraded its Madrigal Pharmaceuticals Inc [MDGL] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. B. Riley Securities revised its rating on February 28, 2025. It rated MDGL as “a Buy” which previously was an “a Neutral”.
Price Performance Review of MDGL
On Tuesday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock jump 7.83% to $444.64. Over the last five days, the stock has gained 3.60%. Madrigal Pharmaceuticals Inc shares have risen nearly 71.45% since the year began. Nevertheless, the stocks have risen 44.10% over the past one year. While a 52-week high of $463.62 was reached on 11/04/25, a 52-week low of $265.00 was recorded on 05/27/25.
Levels Of Support And Resistance For MDGL Stock
The 24-hour chart illustrates a support level at 409.78, which if violated will result in even more drops to 374.91. On the upside, there is a resistance level at 474.73. A further resistance level may holdings at 504.81.
How much short interest is there in Madrigal Pharmaceuticals Inc?
A steep rise in short interest was recorded in Madrigal Pharmaceuticals Inc stocks on 2025-10-15, dropping by -0.45 million shares to a total of 3.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 4.14 million shares. There was a decline of -12.19%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 27, 2025 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $405.
